Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
$10.44
-$0.11(-4.03%)
At close: 4:00 PM EST
$10.44
-$0.11(-4.03%)
Day’s Range― - ―
52-Week Range$1.83 - $12.43
Previous CloseN/A
Volume1.20M
Average Volume (3M)45.45M
Market Cap
$10.73B
Enterprise Value$11.07B
Total Cash (Recent Filing)$242.82M
Total Debt (Recent Filing)$878.12M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
May 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,028,111,500
10 Day Avg. Volume51,424,633
30 Day Avg. Volume45,453,778
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.97
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue97.74
Enterprise Value/Gross Profit105.74
Enterprise Value/Ebitda-49.53
Forecast
1Y Price Target
$10.00Price Target Upside-4.21% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$209.44M
Bulls Say, Bears Say
Bulls Say
Clinical Mechanism And Platform PotentialData showing lymphocyte restoration associated with longer survival across tumor types supports ANKTIVA's potential as a combinable immunotherapy backbone beyond bladder cancer.
Commercial TractionRapid uptake after the U.S. launch and rising unit volumes indicate accelerating physician adoption and support revenue growth as ANKTIVA moves toward an established commercial franchise.
Regulatory ApprovalEuropean conditional marketing authorization for ANKTIVA plus BCG establishes broader regulatory validation and meaningfully expands the therapy's commercial runway across multiple jurisdictions.
Bears Say
Clinical Validation RiskQuestions about the durability and functional quality of restored lymphocytes and whether regulators will accept lymphocyte counts as a meaningful endpoint raise the risk that immune restoration may not secure broader label expansions.
Regulatory ObligationsConditional authorization and required post‑marketing commitments create uncertainty around the timing and scope of confirmatory data submissions, posing regulatory and commercial risk.
Reimbursement And Market AccessUncertainty about national reimbursement decisions in Europe could limit initial market penetration and temper commercial forecasts for ANKTIVA.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.83 and its highest was $12.43 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $10.73B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Mar 03, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.077 by $0.017.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Overvalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.08.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,028,111,500 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.077. Following the earnings report the stock price went down -7.965%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (-4.21% Downside)
$10.00 (-4.21% Downside)
Blogger Sentiment
Bullish
IBRX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.0%
Last 30 Days ▲ 17.1%
Last 30 Days ▲ 17.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.07%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Earnings Call
Q4 2026
0:00 / 0:00
IBRX Stock 12 Month Forecast
Average Price Target
$10.00
▼(-4.21% Downside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
66.40% Insiders
3.47% Mutual Funds
1.00% Other Institutional Investors
23.00% Public Companies and Individual Investors